Myriad Genetics, Inc. (MYGN)
ROA
Obliczenia
|
2023/Q4 (31 gru 2023) |
2023/Q3 (30 wrz 2023) |
2023/Q2 (30 cze 2023) |
2023/Q1 (31 mar 2023) |
2022/Q4 (31 gru 2022) |
2022/Q3 (30 wrz 2022) |
2022/Q2 (30 cze 2022) |
2022/Q1 (31 mar 2022) |
||
|---|---|---|---|---|---|---|---|---|---|
| Zysk netto (ttm) | w tys. USD | -263 300 | -274 400 | -248 200 | -146 200 | -112 000 | -77 300 | -17 600 | -8 200 |
| Aktywa razem | w tys. USD | 1 146 500 | 1 149 100 | 1 187 200 | 1 169 300 | 1 198 700 | 1 212 000 | 1 210 200 | 1 255 400 |
| ROA | -22,97% | -23,88% | -20,91% | -12,50% | -9,34% | -6,38% | -1,45% | -0,65% |
2023/Q4 obliczenia
ROA = Zysk netto (ttm) ÷ Aktywa razem
= $-263 300K ÷ $1 146 500K
= -22,97%
Analiza porównawcza
2023/Q4
Nazwa spółki
Symbol
ROA
Myriad Genetics, Inc.
MYGN
-22,97%
Amphastar Pharmaceuticals Inc
AMPH
9,09%
Arcus Biosciences Inc
RCUS
-28,04%
Catalyst Pharmaceuticals Inc
CPRX
15,19%
Dynavax Technologies Corp.
DVAX
-0,64%
Harmony Biosciences Holdings Inc
HRMY
15,88%
Ironwood Pharmaceuticals Inc
IRWD
-212,76%
Ligand Pharmaceuticals, Inc.
LGND
6,63%
Pacira BioSciences Inc
PCRX
2,66%
Supernus Pharmaceuticals Inc
SUPN
0,10%
Xencor Inc
XNCR
-13,23%